Egalet Corp (EGLT) 15.40 $EGLT Surging Earnings

New Post Public Reply Private Reply Replies (0) Message Board

Mar 21, 2015 at 9:01 PM

Egalet Corp (EGLT) 15.40 $EGLT

Surging Earnings Estimates Signal Good News for Egalet Corp (EGLT) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 19, 7:48AM CDT
The positive earnings estimate revisions suggest that analysts are becoming more optimistic on Egalet Corp's earnings for the coming quarter and year
EGLT: 15.40 (-0.22)

Nasdaq stocks posting largest percentage decreases
AP - Tue Mar 17, 5:16PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
AVID: 15.02 (+0.75), VUZI: 5.91 (-0.05), PGNX: 6.06 (-0.45), EGLT: 15.40 (-0.22), ASPS: 13.33 (+0.85), LJPC: 22.38 (-0.71), ADHD: 5.54 (-0.15), TUES: 16.59 (+0.14), EGRX: 41.00 (-0.11), CBRX: 6.86 (-0.51), TESO: 11.20 (+0.45)

Egalet Earns $10 Million Milestone Payment Triggered by Advancement of Shionogi's Abuse-Deterrent, Extended-Release Hydrocodone, S-718632, Using Egalet's Guardian(TM) Technology
PR Newswire - Tue Mar 17, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"

, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced that the investigational new drug (IND) application submitted by Shionogi to the U.S. Food and Drug Administration (FDA) for the hydrocodone product candidate, S-718632 is now open and active triggering a $10 million milestone payment to Egalet.
EGLT: 15.40 (-0.22)

Egalet (EGLT) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 6:29AM CDT
Egalet (EGLT) Shares March Higher, Can It Continue?
EGLT: 15.40 (-0.22)

Egalet reports FY14 results
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 5:16AM CDT

EGLT: 15.40 (-0.22)

Egalet Reports Full Year 2014 Financial Results
PR Newswire - Mon Mar 16, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"

today reported financial results for the year ended December 31, 2014.
EGLT: 15.40 (-0.22)

Egalet accelerates NDA filing date for abuse-deterrent morphine
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 9:01AM CDT

MNK: 132.47 (+1.26), LCI: 68.57 (-0.32), ACT: 317.06 (+2.65), EGLT: 15.40 (-0.22), ZGNX: 1.38 (+0.02), PFE: 34.25 (+0.10), TEVA: 62.10 (+0.55), ABBV: 60.40 (-0.79), ALKS: 67.20 (-0.86), ACUR: 0.69 (-0.01)

Chronic Pain Therapeutics Pipeline Review 2015 - 62 Companies & 138 Drug Profiles
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98dtzm/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Akron Molecules AG - Allergan, Inc. - arGEN-X BV - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - BCN Peptides, S.A. - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DURECT Corporation - Egalet Corporation - Eli Lilly and Company - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/98...ronic_pain
BDSI: 14.97 (-0.25), ENDP: 92.37 (+0.89), LLY: 76.12 (+1.90), DRRX: 1.68 (-0.01), AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), ACAD: 34.45 (-0.54), EGLT: 15.40 (-0.22), AZN: 72.70 (+1.80), ABBV: 60.40 (-0.79), PTIE: 1.87 (+0.05)

Egalet Accelerates Development of Abuse-Deterrent Morphine Egalet-001 and Plans to File New Drug Application in the Fourth Quarter
PR Newswire - Wed Mar 11, 5:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"

today announced plans to file a new drug application (NDA) by the end of 2015 for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The U.S. Food and Drug Administration (FDA) provided feedback supportive of Egalet's revised investigational plan designed to demonstrate bioequivalence (BE) of Egalet-001 to MS Contin.
EGLT: 15.40 (-0.22)

Collegium Pharma raises $50M to advance abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 7:01AM CDT

MNK: 132.47 (+1.26), LCI: 68.57 (-0.32), EGLT: 15.40 (-0.22), ACT: 317.06 (+2.65), ZGNX: 1.38 (+0.02), PFE: 34.25 (+0.10), ABBV: 60.40 (-0.79), TEVA: 62.10 (+0.55), ALKS: 67.20 (-0.86), ACUR: 0.69 (-0.01)

Egalet to Release 2014 Fourth Quarter and Year-End Financial Results on March 16, 2015 and to Host Conference Call and Webcast to Discuss Commercial Launch on March 25, 2015
PR Newswire - Mon Mar 09, 8:33AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"

today announced that its fourth quarter and year ended December 31, 2014 financial results will be released on Monday, March 16, 2015. In addition, on Wednesday, March 25, 2015, Egalet's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to review the company's commercial plans for OXAYDO(TM) (oxycodone HCl, USP) Tablets for oral use only - CII and SPRIX® (ketorolac tromethamine) Nasal Spray.
EGLT: 15.40 (-0.22)

FDA accepts Teva's NDA for abuse-deterrent opioid
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:42AM CST

MNK: 132.47 (+1.26), LCI: 68.57 (-0.32), ACT: 317.06 (+2.65), EGLT: 15.40 (-0.22), ZGNX: 1.38 (+0.02), PFE: 34.25 (+0.10), ABBV: 60.40 (-0.79), TEVA: 62.10 (+0.55), ALKS: 67.20 (-0.86), ACUR: 0.69 (-0.01)

Egalet (EGLT) Falls: Stock Goes Down 7.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 7:39AM CST
Shares of Egalet (EGLT) fell by nearly 8% on the day. This reverses the recent trend for EGLT as the stock is now up over 60% in the past one-month time frame. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
EGLT: 15.40 (-0.22), IG: 9.32 (+0.65)

Health Care/Biotech Names Still Dominating
Bespoke Investment Group - at Seeking Alpha - Tue Feb 24, 12:33AM CST
The average stock in the Russell 3,000 (which makes up roughly 98% of US-listed stocks) is now up 1.68% in 2015. Below we have calculated the average year-to-date performance of stocks by sector. As shown, Health Care stocks are up by far the most...
XLB: 49.23 (+0.13), XLY: 76.77 (+0.59), XLU: 44.98 (+0.05), XLV: 74.90 (+0.33), NFLX: 428.30 (+3.09), XLP: 48.94 (+0.31), EGLT: 15.40 (-0.22), FMI: 48.11 (-0.29), XLK: 42.54 (+0.10), XLI: 57.12 (+0.06), TWTR: 48.44 (+0.51), XLF: 24.71 (+0.24), XLE: 76.91 (+0.60)

Egalet (EGLT) Shows Strength: Stock Moves 29.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 23, 7:51AM CST
Egalet Corporation (EGLT) was a big mover last session, as the company saw its shares rise over 29% on the day.
LCI: 68.57 (-0.32), EGLT: 15.40 (-0.22)

Egalet adds to HAL study-stoked up move
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 12:37PM CST

EGLT: 15.40 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ROKFORM Unleashes Rangefinder 18X with Bold Features

Strong Magnets and Smarter Tracking: A Golfer's Companion Forget about the agony of misplacing that pricey bit of tech you thought was secure on your golf cart. ROKFORM's new Rangefinder 18X promises to stick around with its bold tech debut. We're talking a magnet on steroids here—up to three times stronger than the competition. If your last purchase slipped on a bumpy...

Grid Hurdles Stalling Industrial Heat's Future Growth

The Grid's the New Ball and Chain Now that we're done fiddling with tech, let's talk grid. The industrial players itching to switch to electric heat have found a new villain: the grid. You'd think with resistance heating, electric boilers, electric arc furnaces, and the whole shebang ready to roll, it’d be a smooth ride. But nope, the bottleneck's the bloodstream...

MLS Org's Sue Compass to Safeguard Fair Listing Access

Real Estate Clash: MLS vs. Compass Imagine flipping on the TV to see a legal showdown brewing in the real estate world — you've got six heavy-hitter MLSs facing off against Compass, Inc. Yeah, we're talking a legal slugfest here, folks, as these MLSs rally to keep the playing field level for over 120,000 agents across the country. They're not messing around, bringing a...

Sheep Meet Solar: Maryland's Agrivoltaics Unfurled

Who would have thought sheep could be power players in Maryland's clean energy scene? But here we are, staring at a field in Cooksville where eighty sheep graze under the watchful gaze of solar panels. It’s not your everyday scene, but it’s a sign of the times when energy meets agriculture head-on. The Unlikely Marriage of Solar and Sheep What we’re looking at is a...

LEDC and Crosson Lead the Charge in Community Finance

Recognizing Game-Changers in Community Development Finance In the financial landscape, it's not always about the big tickers and glitzy IPOs. Sometimes, it's the intrepid ground-level players who make the real difference. That's exactly what happened when the Opportunity Finance Network (OFN) held its 42nd annual conference in New Orleans, honoring standouts in the realm...

College Athletics Needs a New Business Revolution

Wake Up Call for College Athletics Here's a heads-up—college sports aren't just about cheering fans and game-day jerseys anymore. It's high time universities start thinking of athletics as businesses, blending the thrill of game day with the realities of financial statements. Michael Schreiber rang this bell loud and clear on the 'Disruption Interruption' podcast,...

China's Sewing Machine Exports: Global Expansion Surge

China's Position as a Sewing Machine Powerhouse It seems like the global sewing machine market is having a bit of a renaissance, and China's sitting pretty right at the center. You see, places like Taizhou in Zhejiang Province aren’t just pushing out volume—they're slamming market demand with innovation and precision. Once known primarily as the manufacturing hub,...

Frost & Sullivan Boosts China Insight with LeadLeo

Navigating China's Complex Market Landscape You've got to understand, the stakes in China are like a high-wire act—mystifying and risky, yet bountiful if you play your cards right. Frost & Sullivan's latest maneuver into China's business intel scene is basically the lifeline for navigating this increasingly convoluted market. With China surging ahead in AI, biotech, and...

LifeWave's Bold New Path in Human Performance

Redefining the Everyday Athlete Not every day you see a wellness company talking about 'performance' in the broader human sense. Not just for the pros or those beating personal records but for anyone looking to lift the quality of their daily grind. That's the new line LifeWave's drawing in the sand with their spiffy 'Human Performance Technology.' They're looking to...

Monigle's 7 Transform Awards: Building Human Connections

Award-Winning Branding with Heart Alright, let’s dig into Monigle's world—a place where branding isn't just a static logo slapped on anything that moves but is instead about creating alive, breathing experiences that genuinely connect with people. They didn't just turn heads at the Transform Awards North America, they're the ones with jaws dropping, folks. Seven...